You are here:
LinkedIn-button

News

Check here for our latest news

Meet the new Business Development Team

Meet Intravacc’s new Business Development Team. A team of experienced professionals, dedicated to the success of your project.

Meet Intravacc's new Business Development Team. A team of experienced professionals, dedicated to the success of your project.
Read more

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology…

The University of Strathclyde in Glasgow is recognized as a leading international technological university. The appointment of Prof. Schijns will be in the context to further strengthen the pharmacy & biomedical sciences education and research capabilities. During his three years assignment as Visiting Professor Schijns, will teach several courses. He will partake in research discussions and speak during lectures on the relevant areas, as well as participate in series of engagements with students, and academic colleagues.
Read more

Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal…

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal immunity • Data published in the peer reviewed journal MSphere of the American Society of Microbiology
Read more

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that…

  • Randomized, double blinded, placebo-controlled trial
  • Evaluation of two doses in 36 volunteers
  • Mid-term data expected by end Q1 2023
Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 100+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.